Emerging therapeutics for the treatment of Friedreich's ataxia

被引:15
作者
Indelicato, Elisabetta [1 ]
Boesch, Sylvia [1 ]
机构
[1] Innsbruck Med Univ, Neurol Dept, Innsbruck, Austria
来源
EXPERT OPINION ON ORPHAN DRUGS | 2018年 / 6卷 / 01期
关键词
Antioxidants; clinical trials; frataxin upregulation; Friedreich's ataxia; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; TRIPLET REPEAT EXPANSION; CLINICAL PILOT TRIAL; OPEN-LABEL TRIAL; IDEBENONE TREATMENT; MESSENGER-RNA; RATING-SCALE; FOLLOW-UP;
D O I
10.1080/21678707.2018.1409109
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Friedreich ataxia (FRDA) is an autosomal recessive disorder which manifests with progressive instability, leading ultimately to loss of independent gait, dysarthria, skeletal abnormalities and cardiomyopathy. FRDA is caused in 96% of cases by a GAA repeat expansion in the first intron of FXN gene. Pathologic GAA expansions hinder transcriptional activity and result in a reduced expression of the mitochondrial protein frataxin. At a cellular level, frataxin deficiency is accompanied by impaired oxidative phosphorylation, mitochondrial biogenesis and abnormal iron trafficking. From the discovery of disease causing mutation in 1996, combined efforts in basic and clinical research led to the investigation of several potential therapeutic compounds which intervene in different steps of the pathogenetic cascade. Areas covered: In the present review we aimed to critically reappraise current findings from clinical trials in FRDA, including an overview on trial design and preliminary data from ongoing studies. Expert opinion: Despite the several trials finalized in the past years, no therapeutic is currently available for the treatment of FRDA. A number of promising compounds failed to show a significant effect when shifted in a randomized, placebo-controlled setting, because of missing natural history data, poor study design or insufficient preclinical evidence.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 131 条
[1]   Recombinant Human Erythropoietin Increases Frataxin Protein Expression Without Increasing mRNA Expression [J].
Acquaviva, Fabio ;
Castaldo, Imma ;
Filla, Alessandro ;
Giacchetti, Manuela ;
Marmolino, Daniele ;
Monticelli, Antonella ;
Pinelli, Michele ;
Sacca, Francesco ;
Cocozza, Sergio .
CEREBELLUM, 2008, 7 (03) :360-365
[2]   Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS [J].
Adinolfi, Salvatore ;
Iannuzzi, Clara ;
Prischi, Filippo ;
Pastore, Chiara ;
Iametti, Stefania ;
Martin, Stephen R. ;
Bonomi, Franco ;
Pastore, Annalisa .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2009, 16 (04) :390-396
[3]   The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues [J].
Al-Mahdawi, Sahar ;
Pinto, Ricardo Mouro ;
Ismail, Ozama ;
Varshney, Dhaval ;
Lymperi, Stefania ;
Sandi, Chiranjeevi ;
Trabzuni, Daniah ;
Pook, Mark .
HUMAN MOLECULAR GENETICS, 2008, 17 (05) :735-746
[4]   Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich's Ataxia: an Open-Label Trial [J].
Arpa, Javier ;
Sanz-Gallego, Irene ;
Rodriguez-de-Rivera, Francisco J. ;
Dominguez-Melcon, Francisco J. ;
Prefasi, Daniel ;
Oliva-Navarro, Javier ;
Moreno-Yangueela, Mar ;
Pascual-Pascual, Samuel I. .
CEREBELLUM, 2013, 12 (05) :713-720
[5]   Friedreich's ataxia:: Idebenone treatment in early stage patients [J].
Artuch, R ;
Aracil, A ;
Mas, A ;
Colomé, C ;
Rissech, M ;
Monrós, E ;
Pineda, M .
NEUROPEDIATRICS, 2002, 33 (04) :190-193
[6]   Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin [J].
Babcock, M ;
deSilva, D ;
Oaks, R ;
DavisKaplan, S ;
Jiralerspong, S ;
Montermini, L ;
Pandolfo, M ;
Kaplan, J .
SCIENCE, 1997, 276 (5319) :1709-1712
[7]   The cytoprotective role of the Keap1-Nrf2 pathway [J].
Baird, Liam ;
Dinkova-Kostova, Albena T. .
ARCHIVES OF TOXICOLOGY, 2011, 85 (04) :241-272
[8]   E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia [J].
Benini, Monica ;
Fortuni, Silvia ;
Condo, Ivano ;
Alfedi, Giulia ;
Malisan, Florence ;
Toschi, Nicola ;
Serio, Dario ;
Massaro, Damiano Sergio ;
Arcuri, Gaetano ;
Testi, Roberto ;
Rufini, Alessandra .
CELL REPORTS, 2017, 18 (08) :2007-2017
[9]   Selective iron chelation in Friedreich ataxia:: biologic and clinical implications [J].
Boddaert, Nathalie ;
Sang, Kim Hanh Le Quart ;
Roetig, Agnes ;
Leroy-Willig, Anne ;
Gallet, Serge ;
Brunelle, Francis ;
Sidi, Daniel ;
Thalabard, Jean-Christophe ;
Munnich, Arnold ;
Cabantchik, Z. Ioav .
BLOOD, 2007, 110 (01) :401-408
[10]   Neurological Effects of Recombinant Human Erythropoietin in Friedreich's Ataxia: A Clinical Pilot Trial [J].
Boesch, Sylvia ;
Sturm, Brigitte ;
Hering, Sascha ;
Scheiber-Mojdehkar, Barbara ;
Steinkellner, Hannes ;
Goldenberg, Hans ;
Poewe, Werner .
MOVEMENT DISORDERS, 2008, 23 (13) :1940-1944